Does the media refer more to URGN or BLTE?

In the previous week, Urogen Pharma had 2 more articles in the media than Belite Bio. MarketBeat recorded 3 mentions for Urogen Pharma and 1 mentions for Belite Bio. Belite Bio's average media sentiment score of 1.76 beat Urogen Pharma's score of 0.51 indicating that Belite Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Urogen Pharma 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Belite Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has higher valuation and earnings, URGN or LNTH?

Lantheus has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Urogen Pharma $188.73M 10.78 -$153.49M -$1.98 N/A Lantheus $1.56B 4.19 $233.56M $4.14 24.15

Is URGN or LNTH more profitable?

Lantheus has a net margin of 17.69% compared to Urogen Pharma's net margin of -51.73%. Lantheus' return on equity of 28.10% beat Urogen Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Urogen Pharma -51.73% N/A -43.79% Lantheus 17.69% 28.10% 14.35%

Does the media prefer URGN or LNTH?

In the previous week, Lantheus had 4 more articles in the media than Urogen Pharma. MarketBeat recorded 7 mentions for Lantheus and 3 mentions for Urogen Pharma. Lantheus' average media sentiment score of 0.63 beat Urogen Pharma's score of 0.51 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Urogen Pharma 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, LQDA or URGN?

Liquidia has higher earnings, but lower revenue than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liquidia $158.32M 38.16 -$68.92M $1.37 49.26 Urogen Pharma $188.73M 10.78 -$153.49M -$1.98 N/A

Is LQDA or URGN more profitable?

Liquidia has a net margin of 30.74% compared to Urogen Pharma's net margin of -51.73%. Liquidia's return on equity of 149.65% beat Urogen Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Liquidia 30.74% 149.65% 36.30% Urogen Pharma -51.73% N/A -43.79%

Does the media refer more to LQDA or URGN?

In the previous week, Liquidia and Liquidia both had 3 articles in the media. Liquidia's average media sentiment score of 0.54 beat Urogen Pharma's score of 0.51 indicating that Liquidia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Urogen Pharma 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AMRX or URGN?

In the previous week, Amneal Pharmaceuticals had 15 more articles in the media than Urogen Pharma. MarketBeat recorded 18 mentions for Amneal Pharmaceuticals and 3 mentions for Urogen Pharma. Amneal Pharmaceuticals' average media sentiment score of 0.59 beat Urogen Pharma's score of 0.51 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 6 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Urogen Pharma 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor DFTX or URGN?

In the previous week, Definium Therapeutics had 3 more articles in the media than Urogen Pharma. MarketBeat recorded 6 mentions for Definium Therapeutics and 3 mentions for Urogen Pharma. Urogen Pharma's average media sentiment score of 0.51 beat Definium Therapeutics' score of 0.49 indicating that Urogen Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Urogen Pharma 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Urogen Pharma (URGN) Competitors

$41.63 -1.13 (-2.64%)

Closing price 04:00 PM Eastern

Extended Trading

$41.73 +0.10 (+0.25%)

As of 07:30 PM Eastern

Compare

URGN vs. BLTE, LNTH, LQDA, AMRX, and DFTX

Should you buy Urogen Pharma stock or one of its competitors? Urogen Pharma's main competitors and comparable companies include Belite Bio (BLTE), Lantheus (LNTH), Liquidia (LQDA), Amneal Pharmaceuticals (AMRX), and Definium Therapeutics (DFTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Urogen Pharma compare to Belite Bio?

Urogen Pharma (NASDAQ:URGN) and Belite Bio (NASDAQ:BLTE) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

91.3% of Urogen Pharma shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 4.8% of Urogen Pharma shares are owned by company insiders. Comparatively, 13.3% of Belite Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Belite Bio has a net margin of 0.00% compared to Urogen Pharma's net margin of -51.73%. Urogen Pharma's return on equity of 0.00% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Urogen Pharma	-51.73%	N/A	-43.79%
Belite Bio	N/A	-11.84%	-11.62%

Urogen Pharma currently has a consensus price target of $52.38, suggesting a potential upside of 25.81%. Belite Bio has a consensus price target of $218.73, suggesting a potential upside of 29.68%. Given Belite Bio's higher possible upside, analysts clearly believe Belite Bio is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, Urogen Pharma had 2 more articles in the media than Belite Bio. MarketBeat recorded 3 mentions for Urogen Pharma and 1 mentions for Belite Bio. Belite Bio's average media sentiment score of 1.76 beat Urogen Pharma's score of 0.51 indicating that Belite Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Urogen Pharma	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Belite Bio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Urogen Pharma has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market. Comparatively, Belite Bio has a beta of -1.23, meaning that its share price is 223% less volatile than the broader market.

Belite Bio has lower revenue, but higher earnings than Urogen Pharma. Belite Bio is trading at a lower price-to-earnings ratio than Urogen Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Urogen Pharma	$188.73M	10.78	-$153.49M	-$1.98	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A

Summary

Urogen Pharma beats Belite Bio on 8 of the 14 factors compared between the two stocks.

How does Urogen Pharma compare to Lantheus?

Urogen Pharma (NASDAQ:URGN) and Lantheus (NASDAQ:LNTH) are both mid-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

Urogen Pharma presently has a consensus target price of $52.38, suggesting a potential upside of 25.81%. Lantheus has a consensus target price of $108.11, suggesting a potential upside of 8.14%. Given Urogen Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Urogen Pharma is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29

91.3% of Urogen Pharma shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 4.8% of Urogen Pharma shares are owned by company insiders. Comparatively, 1.7% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Lantheus has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Urogen Pharma	$188.73M	10.78	-$153.49M	-$1.98	N/A
Lantheus	$1.56B	4.19	$233.56M	$4.14	24.15

Lantheus has a net margin of 17.69% compared to Urogen Pharma's net margin of -51.73%. Lantheus' return on equity of 28.10% beat Urogen Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Urogen Pharma	-51.73%	N/A	-43.79%
Lantheus	17.69%	28.10%	14.35%

In the previous week, Lantheus had 4 more articles in the media than Urogen Pharma. MarketBeat recorded 7 mentions for Lantheus and 3 mentions for Urogen Pharma. Lantheus' average media sentiment score of 0.63 beat Urogen Pharma's score of 0.51 indicating that Lantheus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Urogen Pharma	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Urogen Pharma has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, suggesting that its share price is 103% less volatile than the broader market.

Summary

Lantheus beats Urogen Pharma on 10 of the 16 factors compared between the two stocks.

How does Urogen Pharma compare to Liquidia?

Liquidia (NASDAQ:LQDA) and Urogen Pharma (NASDAQ:URGN) are both mid-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

Liquidia presently has a consensus price target of $98.08, suggesting a potential upside of 45.33%. Urogen Pharma has a consensus price target of $52.38, suggesting a potential upside of 25.81%. Given Liquidia's higher possible upside, research analysts plainly believe Liquidia is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.55
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

64.5% of Liquidia shares are held by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are held by institutional investors. 25.6% of Liquidia shares are held by company insiders. Comparatively, 4.8% of Urogen Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Liquidia has a net margin of 30.74% compared to Urogen Pharma's net margin of -51.73%. Liquidia's return on equity of 149.65% beat Urogen Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	30.74%	149.65%	36.30%
Urogen Pharma	-51.73%	N/A	-43.79%

In the previous week, Liquidia and Liquidia both had 3 articles in the media. Liquidia's average media sentiment score of 0.54 beat Urogen Pharma's score of 0.51 indicating that Liquidia is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Urogen Pharma	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Liquidia has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market. Comparatively, Urogen Pharma has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market.

Liquidia has higher earnings, but lower revenue than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	38.16	-$68.92M	$1.37	49.26
Urogen Pharma	$188.73M	10.78	-$153.49M	-$1.98	N/A

Summary

Liquidia beats Urogen Pharma on 11 of the 16 factors compared between the two stocks.

How does Urogen Pharma compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Urogen Pharma (NASDAQ:URGN) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

Amneal Pharmaceuticals has a net margin of 5.05% compared to Urogen Pharma's net margin of -51.73%. Urogen Pharma's return on equity of 0.00% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%
Urogen Pharma	-51.73%	N/A	-43.79%

In the previous week, Amneal Pharmaceuticals had 15 more articles in the media than Urogen Pharma. MarketBeat recorded 18 mentions for Amneal Pharmaceuticals and 3 mentions for Urogen Pharma. Amneal Pharmaceuticals' average media sentiment score of 0.59 beat Urogen Pharma's score of 0.51 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	6 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Urogen Pharma	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amneal Pharmaceuticals has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market. Comparatively, Urogen Pharma has a beta of 1.57, indicating that its stock price is 57% more volatile than the broader market.

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Comparatively, 4.8% of Urogen Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Amneal Pharmaceuticals has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.12B	1.98	$72.06M	$0.49	39.45
Urogen Pharma	$188.73M	10.78	-$153.49M	-$1.98	N/A

Amneal Pharmaceuticals currently has a consensus price target of $21.00, indicating a potential upside of 8.64%. Urogen Pharma has a consensus price target of $52.38, indicating a potential upside of 25.81%. Given Urogen Pharma's higher possible upside, analysts plainly believe Urogen Pharma is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Summary

Amneal Pharmaceuticals beats Urogen Pharma on 11 of the 16 factors compared between the two stocks.

How does Urogen Pharma compare to Definium Therapeutics?

Definium Therapeutics (NASDAQ:DFTX) and Urogen Pharma (NASDAQ:URGN) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Definium Therapeutics presently has a consensus price target of $64.88, indicating a potential upside of 72.31%. Urogen Pharma has a consensus price target of $52.38, indicating a potential upside of 25.81%. Given Definium Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Definium Therapeutics is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	3.00
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

27.9% of Definium Therapeutics shares are owned by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are owned by institutional investors. 2.4% of Definium Therapeutics shares are owned by insiders. Comparatively, 4.8% of Urogen Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Urogen Pharma has higher revenue and earnings than Definium Therapeutics. Urogen Pharma is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A
Urogen Pharma	$188.73M	10.78	-$153.49M	-$1.98	N/A

Definium Therapeutics has a beta of 2.23, meaning that its stock price is 123% more volatile than the broader market. Comparatively, Urogen Pharma has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market.

In the previous week, Definium Therapeutics had 3 more articles in the media than Urogen Pharma. MarketBeat recorded 6 mentions for Definium Therapeutics and 3 mentions for Urogen Pharma. Urogen Pharma's average media sentiment score of 0.51 beat Definium Therapeutics' score of 0.49 indicating that Urogen Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Urogen Pharma	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Definium Therapeutics has a net margin of 0.00% compared to Urogen Pharma's net margin of -51.73%. Urogen Pharma's return on equity of 0.00% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-84.01%	-63.66%
Urogen Pharma	-51.73%	N/A	-43.79%

Summary

Definium Therapeutics and Urogen Pharma tied by winning 8 of the 16 factors compared between the two stocks.

Get Urogen Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding URGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

URGN vs. The Competition

Export

Metric	Urogen Pharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.03B	$12.42B	$7.21B	$13.10B
Dividend Yield	N/A	2.63%	2.53%	13.00%
P/E Ratio	-21.03	794.80	274.58	25.69
Price / Sales	10.78	830.70	648.78	85.88
Price / Cash	N/A	86.22	76.31	52.02
Price / Book	-18.50	10.62	10.44	6.32
Net Income	-$153.49M	$2.81B	$3.49B	$359.73M
7 Day Performance	-4.28%	0.73%	0.51%	1.35%
1 Month Performance	-11.16%	-1.67%	-3.38%	-3.68%
1 Year Performance	132.83%	3.07%	16.04%	5.56%

Urogen Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
URGN Urogen Pharma	2.7318 of 5 stars	$41.63 -2.6%	$52.38 +25.8%	+137.7%	$2.03B	$188.73M	N/A	291
BLTE Belite Bio	4.002 of 5 stars	$169.21 -0.1%	$218.73 +29.3%	+146.0%	$6.82B	N/A	N/A	41	Positive News
LNTH Lantheus	3.8267 of 5 stars	$100.54 -0.2%	$108.11 +7.5%	+99.6%	$6.57B	$1.54B	24.29	1,193	News Coverage
LQDA Liquidia	3.5928 of 5 stars	$68.45 +4.2%	$98.08 +43.3%	+199.7%	$5.88B	$158.32M	49.96	216	Analyst Upgrade
AMRX Amneal Pharmaceuticals	3.2851 of 5 stars	$18.08 +8.6%	$19.57 +8.2%	+95.0%	$5.32B	$3.02B	19.36	8,500	News Coverage Analyst Forecast High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:URGN) was last updated on 9/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Urogen Pharma (URGN) Competitors

URGN vs. BLTE, LNTH, LQDA, AMRX, and DFTX

How does Urogen Pharma compare to Belite Bio?

Summary

How does Urogen Pharma compare to Lantheus?

Summary

How does Urogen Pharma compare to Liquidia?

Summary

How does Urogen Pharma compare to Amneal Pharmaceuticals?

Summary

How does Urogen Pharma compare to Definium Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

URGN vs. The Competition

Urogen Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Urogen Pharma (URGN) Competitors

URGN vs. BLTE, LNTH, LQDA, AMRX, and DFTX

How does Urogen Pharma compare to Belite Bio?

Do institutionals and insiders hold more shares of URGN or BLTE?

Is URGN or BLTE more profitable?

Do analysts prefer URGN or BLTE?

Does the media refer more to URGN or BLTE?

Which has more risk and volatility, URGN or BLTE?

Which has stronger earnings and valuation, URGN or BLTE?

Summary

How does Urogen Pharma compare to Lantheus?

Do analysts prefer URGN or LNTH?

Do institutionals and insiders hold more shares of URGN or LNTH?

Which has higher valuation and earnings, URGN or LNTH?

Is URGN or LNTH more profitable?

Does the media prefer URGN or LNTH?

Which has more volatility & risk, URGN or LNTH?

Summary

How does Urogen Pharma compare to Liquidia?

Do analysts recommend LQDA or URGN?

Do institutionals and insiders believe in LQDA or URGN?

Is LQDA or URGN more profitable?

Does the media refer more to LQDA or URGN?

Which has more volatility and risk, LQDA or URGN?

Which has higher valuation & earnings, LQDA or URGN?

Summary

How does Urogen Pharma compare to Amneal Pharmaceuticals?

Is AMRX or URGN more profitable?

Does the media refer more to AMRX or URGN?

Which has more volatility and risk, AMRX or URGN?

Do insiders and institutionals have more ownership in AMRX or URGN?

Which has preferable earnings & valuation, AMRX or URGN?

Do analysts prefer AMRX or URGN?

Summary

How does Urogen Pharma compare to Definium Therapeutics?

Do analysts rate DFTX or URGN?

Do insiders and institutionals believe in DFTX or URGN?

Which has preferable valuation & earnings, DFTX or URGN?

Which has more risk and volatility, DFTX or URGN?

Does the media favor DFTX or URGN?

Is DFTX or URGN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

URGN vs. The Competition

Urogen Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools